Treatment of rheumatoid arthritis with roxithromycin: A randomized trial

Postgraduate Medicine

Volumn 123, Issue 5, 2011, Pages 220-227

  Ogrendik, Mesut ^a   Karagoz, Nihan ^b  

^a Nazilli State Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Macrolide antibiotics; Periodontal disease; Porphyromonas; Rheumatoid arthritis; Roxithromycin

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; ROXITHROMYCIN;

ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; ROXITHROMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052708726     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.09.2478     Document Type: Article

References (41)

1. Feely MG, Erickson A, O'Dell JR. Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother. 2009;10(13):2095-2106.
2. de Pablo P, Chapple IL, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol. 2009;5(4):218-224.
3. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. J Periodontol. 2001;72(6): 779-787.
4. Detert J, Pischon N, Burmester GR, Buttgereit F. The association between rheumatoid arthritis and periodontal disease. Arthritis Res Ther. 2010;12(5):218.
5. Bonfi JJ, Dillier FL, Mercier P, et al. A "case control" study on the role of HLA DR4 in severe periodontitis and rapidly progressive periodontitis. Identifi cation of types and subtypes using molecular biology (PCR. SSO). J Clin Periodontol. 1999;26(2):77-84.
6. Gran JT, Husby G, Thorsby E. The association between rheumatoid arthritis and HLA antigen DR4. Ann Rheum Dis. 1983;42(3): 292-296.
7. Al-Katma MK, Bissada NF, Bordeaux JM, Sue J, Askari AD. Control of periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol. 2007;13(3):134-137.
8. Moen K, Brun JG, Madland TM, Tynning T, Jonsson R. Immunoglobulin G and A antibody responses to Bacteroides forsythus and Prevotella intermedia in sera and synovial fl uids of arthritis patients. Clin Diagn Lab Immunol. 2003;10(6):1043-1050.
9. Ogrendik M, Kokino S, Ozdemir F, Bird PS, Hamlet S. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. MedGenMed. 2005;7(2):2.
10. Moen K, Brun JG, Valen M, et al. Synovial infl ammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol. 2006;24(6):656-663.
11. Ogrendik M. Effi cacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial. Clin Ther. 2009;31(8):1754-1764.
12. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin. 2007;23(3):515-522.
13. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebocontrolled study. Arthritis Rheum. 1993;36(11):1501-1509.
14. Das KM. Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol Clin North Am. 1989;18(1):1-20.
15. Oyama T, Matsushita K, Sakuta T, et al. Roxithromycin inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-1 expression through regulating mitogen-activated protein kinase phosphorylation and Ets-1 expression. J Periodontal Res. 2007;42(1):53-61.
16. Furst DE, Saag K, Fleischmann MR, et al. Effi cacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002;46(8):2020-2028.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
18. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modifi ed Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26(4):1346-1353.
19. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789-793.
20. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729-740.
21. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary defi nition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735.
22. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modifi ed disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.
23. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 suppl 39):S93-S99.
24. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43(10):1252-1255.
25. Vrijhoef HJ, Diederiks JP, Spreeuwenberg C, Van der Linden S. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):419-422.
26. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA. 1996;93(24):14014-14019.
27. Tilley BC, Alarcón GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med. 1995;122(2):81-89.
28. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis. A double-blind, placebocontrolled trial. Arthritis Rheum. 1994;37(5):629-636.
29. O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1997;40(5): 842-848.
30. O'Dell JR, Paulsen G, Haire CE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum. 1999; 42(8):1691-1695.
31. Modi DK, Chopra VS, Bhau U. Rheumatoid arthritis and periodontitis: biological links and the emergence of dual purpose therapies. Indian J Dent Res. 2009;20(1):86-90.
32. van der Heijden IM, Wilbrink B, Tchetverikov I, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum. 2000;43(3):593-598.
33. Martinez-Martinez RE, Abud-Mendoza C, Patiño-Marin N, et al. Detection of periodontal bacterial DNA in serum and synovial fl uid in refractory rheumatoid arthritis patients. J Clin Periodontol. 2009;36(12):1004-1010.
34. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337(3):141-147.
35. Seymour GJ, Gemmell E. Cytokines in periodontal disease: where to from here? Acta Odontol Scand. 2001;59(3):167-173.
36. Yoshimura A, Hara Y, Kaneko T, Kato I. Secretion of IL-1 beta, TNF-alpha, IL-8 and IL-1ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria. J Periodontal Res. 1997;32(3):279-286.
37. Kjeldsen M, Holmstrup P, Lindemann RA, Bendtzen K. Bacterialstimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. J Periodontol. 1995;66(2):139-144.
38. Rossano F, Rizzo A, Sanges MR, Cipollaro de L'Ero G, Tufano MA. Human monocytes and gingival fi broblasts release tumor necrosis factoralpha, interleukin-1 alpha and interleukin-6 in response to particulate and soluble fractions of Prevotella melaninogenica and Fusobacterium nucleatum. Int J Clin Lab Res. 1993;23(3):165-168.
39. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292(1): 156-163.
40. Urasaki Y, Nori M, Iwata S, et al. Roxithromycin specifi cally inhibits development of collagen induced arthritis and production of proinfl amatory cytokines by human T cells and macrophages. J Rheumatol. 2005;32(9):1765-1774.
41. Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase production from nasal fi broblasts by macrolide antibiotics in vitro. Eur Respir J. 2004;23(5):671-678.